BSI-045B is also being advanced in multiple Phase 2 studies in China by Biosion’s regional partner, Chia Tai Tianqing ...

Leerink Partners, a leading investment bank specializing in healthcare, is pleased to announce the addition of Holden Hodgson as Senior Managing Director, Derivatives. Mr. Hodgson will be based in the ...

Leerink Partners, the health-care advisory firm, has continued a recent recruitment drive with hires from boutiques ...

On Monday, Cardinal Health Inc (CAH) stock saw a modest uptick, ending the day at $120.03 which represents a slight increase of $1.25 or 1.05% from the prior close of $118.78. The stock opened at $118 ...

Equities researchers at Leerink Partnrs reduced their FY2024 earnings per share estimates for shares of Lexeo Therapeutics in ...

Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and reduced ...

Leerink Partners analyst Andrew Berens reiterated a Buy rating on Cullinan Management (CGEM – Research Report) yesterday and set a price target ...

On Monday, 10X Genomics Inc (TXG) stock saw a decline, ending the day at $13.18 which represents a decrease of $-0.16 or -1.20% from the prior close of $13.34. The stock opened at $13.34 and touched a ...

Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

Bristol-Myers Squibb (BMY) stock was upgraded by Leerink Partners based on a potential sales boost for its schizophrenia ...

Don't Miss our Black Friday Offers: Hims & Hers Health (HIMS) Leerink Partners analyst Michael Cherny maintained a Hold rating on Hims & Hers Health on November 14 and set a price target of $24.00.

Fintel reports that on November 7, 2024, Leerink Partners upgraded their outlook for Zymeworks (NasdaqGS:ZYME) from Market ...